Abstract
The World Health Organization has called for the elimination of hepatitis C virus (HCV) as a public health threat by 2030. Highly effective direct-acting antiviral agents provide the therapeutic tools required for elimination. In the absence of a vaccine, HCV elimination will require enhanced primary prevention and an increase in the proportions of people diagnosed and treated. Given that globally only 20% of people with chronic HCV are diagnosed, and around 5% have initiated HCV treatment, the task ahead is enormous. But, global public health needs optimism, and countries currently on track for HCV elimination provide a pathway forward.
Keywords:
Direct-acting antivirals; Elimination; Global health; Hepatitis C; People who inject drugs; Sustainable development goals; Treatment; Universal health coverage.
Copyright © 2020 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
2-Naphthylamine
-
Anilides / administration & dosage
-
Antiviral Agents / administration & dosage*
-
Antiviral Agents / economics
-
Benzofurans / administration & dosage
-
Carbamates / administration & dosage
-
Drug Therapy, Combination
-
Global Health
-
Health Care Costs
-
Hepatitis C, Chronic / diagnosis
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / economics
-
Hepatitis C, Chronic / prevention & control*
-
Humans
-
Imidazoles / administration & dosage
-
Proline
-
Pyrrolidines
-
Sofosbuvir / administration & dosage
-
Sulfonamides / administration & dosage
-
Uracil / administration & dosage
-
Uracil / analogs & derivatives
-
Valine / analogs & derivatives
-
World Health Organization
Substances
-
Anilides
-
Antiviral Agents
-
Benzofurans
-
Carbamates
-
Imidazoles
-
Pyrrolidines
-
Sulfonamides
-
ombitasvir
-
Uracil
-
elbasvir
-
Proline
-
2-Naphthylamine
-
dasabuvir
-
Valine
-
daclatasvir
-
Sofosbuvir